Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Susan Morrison - Executive Vice President and Chief Administrative Officer John Sheridan - President and Chief Executive Officer Brian Hansen - Executive Vice President and Chief Commercial Officer Leigh Vosseller - Executive Vice President and Chief Financial Officer Conference Call Participants Matthew Miksic - Barclays Steven Lichtman - Oppenheimer Christopher Pasquale - Nephron Research ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Trans ...

Company Overview FEBRUARY 22, 2023 Safe Harbor CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain statements in this presentation constitute forward-looking statements, including, without limitation, statements about: the perceived advantages of our products relative to competitive products and technologies; our anticipated growth and other measures of future operating results and financial performance; the development and commercialization of new products; our ability to secure and maintain neces ...

Financial Data and Key Metrics Changes - In 2022, the company achieved sales exceeding $800 million, more than doubling sales in three years [19] - Fourth quarter sales were $221 million on a GAAP basis and $223 million on a non-GAAP basis, with 36,000 pump shipments worldwide [19][20] - The gross margin for 2022 was 52%, down from 54% in 2021, attributed to higher raw material costs [25][26] Business Line Data and Key Metrics Changes - Pumps accounted for 54% of total sales, with a 60% increase in renewal shipments for the year [19][21] - In the U.S., 2022 sales were $589 million on a GAAP basis, with a 20% increase in the installed base to 290,000 customers [20][21] - International sales reached $212 million, growing 19% year-over-year, driven by a 35% increase in supply sales [21][22] Market Data and Key Metrics Changes - The U.S. insulin pump market remains over 35% penetrated, while international markets are typically only 10% to 20% penetrated [9] - Approximately 20% growth in people adopting t:slim technology across more than 25 countries, with Q4 being the strongest quarter [8][9] Company Strategy and Development Direction - The company aims to expand the insulin pump market and enhance awareness of its Control-IQ technology while preparing for multiple new product launches [10][23] - Recent acquisitions of Capillary Biomedical and AMF Medical align with the strategic vision to increase insulin pump adoption worldwide [6][9] - The company is focused on creating a portfolio of technology solutions that cater to diverse needs and preferences of diabetes patients [17] Management's Comments on Operating Environment and Future Outlook - Management noted that the operating environment remains consistent, with no significant changes in competition or market conditions anticipated [37] - The company expects 2023 worldwide sales guidance of $885 million to $900 million, reflecting a growth rate of 10% to 12% [23][30] - Adjusted EBITDA margins are expected to be negative in the first half of 2023 but return to positive in the second half [28][30] Other Important Information - The company completed the transfer of its t:slim cartridge lines to a third-party manufacturer to scale production for the new Tandem Mobi pump [11] - The launch of the t:slim X2 with G7 integration is planned for later in Q2, aiming to be the first to market with this integration in an AID system [14] Q&A Session Summary Question: Can you walk us through the margin direction and the factors affecting the EBITDA number? - Management indicated that gross margin improvements are expected from pricing and cost efficiencies, with new product launches providing future benefits [33][34] Question: What impacts are being seen from the softening economy and competition? - Management noted that the environment has remained consistent, with no significant changes in competition observed [36][37] Question: What is the expectation for new patient starts in the U.S.? - Management acknowledged that new patient starts are expected to be pressured, but renewals will continue to drive growth [39][40] Question: How is the company preparing for the Mobi launch? - Management is responding to FDA questions and plans for a scaled launch in the second half of the year, with preparations underway [66][67] Question: What is the outlook for international markets? - Management highlighted a significant opportunity in international markets, with a focus on expanding penetration and attracting competitive conversions [44]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________ FORM 10-K _________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36189 ______ ...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q3 2022 Results Conference Call November 2, 2022 4:30 PM ET Company Participants Susan Morrison - Executive VP & Chief Administrative Officer John Sheridan - President, CEO & Director Leigh Vosseller - EVP, CFO & Treasurer Conference Call Participants Matt Miksic - Barclays Brooks O'Neil - Lake Street Capital Partners Chris Pasquale - Nephron Research Matthew O'Brien - Piper Sandler Steve Litchman - Oppenheimer Matt Taylor - Jefferies Alex Nowak - Craig-Hallum Jayson ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the T ...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Susan Morrison - Executive VP & Chief Administrative Officer John Sheridan - President, CEO & Director Brian Hansen - EVP & Chief Commercial Officer Leigh Vosseller - EVP, CFO & Treasurer Conference Call Participants Steven Lichtman - Oppenheimer Brooks O'Neil - Lake Street Capital Markets Travis Steed - Bank of America Merrill Lynch Jayson Bedford - Raymond James & Associates Matthew O'B ...

Financial Performance - Sales for the three months ended June 30, 2022, were $200,262 thousand, a 16.3% increase from $172,139 thousand in the same period of 2021[11] - Gross profit for the six months ended June 30, 2022, was $193,039 thousand, up 16.5% from $165,741 thousand in the prior year[11] - The net loss for the three months ended June 30, 2022, was $15,056 thousand, compared to a net income of $4,008 thousand in the same period of 2021[11] - For the six months ended June 30, 2022, the net loss increased to $29.77 million compared to a net loss of $1.036 million for the same period in 2021[20] - The company reported a comprehensive loss of $16,277 thousand for the three months ended June 30, 2022, compared to a comprehensive income of $3,931 thousand in the same period of 2021[11] - Total sales for the three months ended June 30, 2022, were $200.3 million, a 16.3% increase from $172.1 million in the same period in 2021[156] - Total sales for the six months ended June 30, 2022, were $376.2 million, a 20.1% increase from $313.2 million in the same period in 2021[169] Assets and Liabilities - Total assets increased to $1,036,575 thousand as of June 30, 2022, compared to $905,137 thousand at December 31, 2021, representing a growth of 14.5%[10] - Total liabilities increased to $586,991 thousand as of June 30, 2022, from $472,025 thousand at December 31, 2021, an increase of 24.3%[10] - Cash and cash equivalents increased to $114,966 thousand as of June 30, 2022, from $71,181 thousand at December 31, 2021, reflecting a growth of 61.3%[10] - The company’s total stockholders' equity decreased to $346.09 million as of June 30, 2021, from $366.31 million at the end of 2020[16] - The company’s accounts receivable, net, was $103.763 million as of June 30, 2022, down from $110.725 million at December 31, 2021[49] Expenses - Operating expenses rose to $114,185 thousand for the three months ended June 30, 2022, compared to $87,022 thousand in the same period of 2021, marking a 31.2% increase[11] - Research and development expenses for the six months ended June 30, 2022, were $66,731 thousand, a significant increase of 73.6% from $38,460 thousand in the prior year[11] - Selling, general and administrative expenses rose 21% to $80.6 million for the three months ended June 30, 2022, from $66.5 million in the same period in 2021[164] - SG&A expenses increased by 23% to $153.9 million for the first six months of 2022, primarily due to a $22.8 million rise in employee-related expenses[176] Cash Flow - The company reported net cash provided by operating activities of $20.70 million for the six months ended June 30, 2022, a decrease from $57.58 million in the same period of 2021[20] - Net cash provided by operating activities was $20.7 million for the first six months of 2022, a decrease from $57.6 million in the same period of 2021, attributed to a $28.7 million increase in net loss[185] Stock and Equity - The weighted average shares used to compute basic net loss per share for the three months ended June 30, 2022, were 64,077 thousand, compared to 62,717 thousand in the same period of 2021[11] - As of June 30, 2022, a total of 10,402 thousand shares were reserved for future issuance, including 2,554 thousand shares for Convertible Senior Notes conversion[81] - The total number of stock options granted in Q2 2022 was 83,008, with a weighted average grant date fair value of $42.16 per share, compared to 239,608 options in Q2 2021 at $54.92 per share[86] Legal and Regulatory - The Company is involved in ongoing legal proceedings related to data breaches and employment claims, which may impact its financial condition, although the ultimate outcomes remain uncertain[99][100][101] - The company is involved in ongoing legal proceedings related to a data breach and labor code violations, with potential financial implications[207][208] Product Development and Market Performance - The company launched a mobile bolus feature for the t:slim X2 in July 2022, the first FDA-cleared smartphone app for insulin delivery[114] - The company is developing the Mobi insulin pump, which is approximately half the size of the t:slim X2 and designed for greater discretion and flexibility[120] - The t:slim X3 is being designed to enhance usability with a modernized interface and increased processing power[121] - The company has initiated clinical studies to expand the indications of its Control-IQ technology to include children aged 2 to 5 years and individuals with type 2 diabetes[126] - The company has entered into agreements with Dexcom and Abbott to integrate their CGM technologies with its insulin delivery systems[129][130] Market Trends and Sales Variability - The company anticipates ongoing variability in sales and operating results due to the impact of the COVID-19 pandemic[116][117] - The impact of the COVID-19 pandemic has introduced variability in sales trends, with the company anticipating unpredictable fluctuations in the coming months[145] Financial Instruments and Risk Management - The company maintains liquidity and preserves principal while maximizing income from financial instruments, with guidelines established for approved investments[197] - The company has limited exposure to foreign currency exchange rate risk, primarily related to operations in Canada, and may use derivative instruments to hedge such risks[200]

Financial Data and Key Metrics Changes - First quarter sales reached $176 million, reflecting a year-over-year growth rate of 25% [26] - Gross margin remained stable at 52%, with production cost improvements and increased average selling prices contributing to this performance [31] - Adjusted EBITDA margin was positive at 4% of sales, while operating margin was negative at 9% of sales [34] Business Line Data and Key Metrics Changes - In the US, first quarter sales grew 27% to $131 million, with nearly 19,000 pumps shipped, resulting in an installed base of over 250,000 customers [27] - International sales totaled $45 million, an 18% increase year-over-year, with over 9,000 pumps shipped [28] - Renewals accounted for nearly 20% of total pumps shipped in the quarter, up from approximately 15% in the prior year [27] Market Data and Key Metrics Changes - The installed base surpassed 350,000 people worldwide, representing about 30% of insulin pump users in served geographies [11] - Customer retention remained strong, with half of new US customers in Q1 converting from multiple daily injections [11] - The company noted variability in shipment patterns due to inventory rebalancing among key distributors, which does not reflect underlying market demand [29] Company Strategy and Development Direction - The company aims to expand the insulin pump market and enhance customer experience through innovations like the mobile bolus delivery feature [15][17] - A focus on R&D investment, with R&D expenses expected to average 15% of sales for the year, supports hardware, software, and digital health initiatives [34] - The Mobi pump, designed for mobile app control, is a key development project aimed at serving a new market segment [19] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the broader COVID and economic trends impacting the market and healthcare providers [30] - The company anticipates continued challenges from labor shortages and fluctuating COVID case rates affecting physician offices [18] - Full-year sales expectations have been increased to a range of $850 million to $865 million, reflecting strong Q1 results [30] Other Important Information - The company ended the quarter with $635 million in cash and investments, generating free cash flow of $11 million [36] - The Control-IQ technology continues to receive positive feedback, enhancing customer satisfaction and quality of life [12] Q&A Session Summary Question: Intra-quarter trends and impact of Omicron - Management noted that the beginning of the quarter was pressured due to illnesses, but there was an uptick as the quarter progressed [41] Question: Competitive environment in OUS markets - Management indicated that OUS markets faced similar challenges as the US, with no significant changes in competition [52] Question: Type 2 market focus and timeline - A feasibility study for Type 2 is underway, with pivotal study expected in early 2023, targeting late 2023 or 2024 for product launch [56] Question: Factors contributing to pump shipment growth - Strong performance was attributed to new customer growth and increased renewals, indicating a positive trend for future opportunities [61] Question: International distributor inventory levels - Management confirmed that inventory levels are expected to normalize, with standard ordering anticipated in the second quarter [89]